

GenCore version 5.1.3
Copyright (c) 1993 - 2002 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 12, 2002, 13:02:35 : Search time 180 Seconds
(without alignments)
3719.981 Million cell updates/sec

Title: US-09-818-954A-2

Perfect score: 390
1 atgaagctgcatctctt.....ccacgagtgtagaccatc 390

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1736436 seqs, 858457221 residues

Total number of hits satisfying chosen parameters: 3472872

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_032802: *
1: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT: *
2: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT: *
3: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT: *
4: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT: *
5: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT: *
6: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT: *
7: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT: *
8: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT: *
9: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT: *
10: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT: *
11: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT: *
12: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT: *
13: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT: *
14: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT: *
15: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT: *
16: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT: *
17: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT: *
18: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT: *
19: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT: *
20: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT: *
21: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT: *
22: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT: *
23: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT: *
24: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT: *

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	390	100.0	390	22 AAH46586	Human anterior pit
2	390	100.0	390	22 AAS17500	Human encoding human
3	390	100.0	393	22 AAD16347	Human spghsta gene
4	390	100.0	917	22 AAH42567	Nucleotide sequenc
5	378	96.9	693	22 AAR3867	Human novel gonado
6	318	81.5	318	22 AAH46589	Human anterior pit
7	300.4	77.0	393	24 AAS17508	DNA encoding mouse
8	290.8	74.6	387	22 AAH46593	Rat anterior pitui
9	260	66.7	318	22 AAH46594	Rat anterior pitui

10	252	64.6	1045	22 AAH42568	Nucleotide sequenc
11	156	40.0	2985	24 AAS17518	Genomic DNA encodi
12	61.6	15.8	496	7 AAN60523	Sequence encoding
13	57.8	14.8	525	11 AAQ03844	Bovine beta LH sub
14	56.8	14.6	535	22 AAH41044	gth-beta1I subunit
15	56.8	14.6	5651	22 AAI616195	Human FSH beta enc
16	53	13.6	524	19 AAV35322	Equine chorionic g
17	53	13.6	611	11 AAQ03848	Equine beta LH sub
18	51.4	13.2	843	19 AAV35323	Equine chorionic g
19	50.4	12.9	616	11 AAQ03850	Equine beta FSH su
20	50.2	12.9	486	10 AAN91176	Sequence encoding
21	48.8	12.5	278	21 AAC71485	Single nucleotide
22	48.8	12.5	309	21 AAC61706	DNA encoding a bet
23	48.8	12.5	312	21 AAC61704	DNA encoding a bet
24	48.8	12.5	312	21 AAC61705	DNA encoding a bet
25	48.8	12.5	315	21 AAC61694	DNA encoding a bet
26	48.8	12.5	315	21 AAC61702	DNA encoding a bet
27	48.8	12.5	315	21 AAC61703	DNA encoding a bet
28	48.8	12.5	318	21 AAC61693	DNA encoding a bet
29	48.8	12.5	318	21 AAC61700	DNA encoding a bet
30	48.8	12.5	318	21 AAC61701	DNA encoding a bet
31	48.8	12.5	321	21 AAC61692	DNA encoding a bet
32	48.8	12.5	321	21 AAC61698	DNA encoding a bet
33	48.8	12.5	321	21 AAC61699	DNA encoding a bet
34	48.8	12.5	324	21 AAC61688	DNA encoding a bet
35	48.8	12.5	324	21 AAC61697	DNA encoding a bet
36	48.8	12.5	324	21 AAZ45452	Nucleotide sequenc
37	48.8	12.5	327	21 AAC61690	DNA encoding a bet
38	48.8	12.5	327	21 AAC61695	DNA encoding a bet
39	48.8	12.5	327	21 AAZ45454	Nucleotide sequenc
40	48.8	12.5	330	21 AAC61691	DNA encoding a bet
41	48.8	12.5	330	21 AAZ45455	Nucleotide sequenc
42	48.8	12.5	333	21 AAC61687	DNA encoding the b
43	48.8	12.5	333	21 AAZ45451	Nucleotide sequenc
44	48.8	12.5	348	18 AAT88947	Human beta follicl
45	48.8	12.5	348	18 AAT88949	Human beta follicl

ALIGNMENTS

RESULT 1
AAH46586
ID AAH46586 standard; DNA; 390 BP.
XX
AC AAH46586;
AC
DT 17-SEP-2001 (first entry)
XX
DE Human anterior pituitary hormone-related polynucleotide #1.
XX
KW Human; anterior pituitary hormone; hypertension; autoimmune disease;
KW heart failure; ds.
XX
OS Homo sapiens.
XX
PM W0200144475-A1.
XX
PD 21-JUN-2001.
XX
PF 15-DEC-2000; 2000WO-JP08896.
XX
PR 17-DEC-1999; 99JP-0358707.
PR 18-FEB-2000; 2000JP-0046825.
PA (TAKE) TAKEDA CHEM IND LTD.
PA Hinuma S, Fukusumi S, Fujii R, Hosoya M;
PI WPT: 2001-408485/43.
XX P-PSDB: AAG64064.
XX
XX Polypeptides for treatment of hypertension, autoimmune disease and

FT	heart failure -
XX	
PS	Claim 7; Fig 1; 107pp; Japanese.
CC	The invention relates to a novel polypeptide comprising a fully defined
CC	130 amino acid sequence given in the specification and its amides,
CC	esters and salts. The polypeptide has anterior pituitary hormone-related
CC	activity. It is useful for the treatment of hypertension, autoimmune
CC	diseases and heart failure. The screening method and kit also
CC	provided in the invention are useful for identifying new substances
CC	for treating and preventing these diseases. The present sequence encodes
CC	the polypeptide of the invention.
XX	
SQ	Sequence 390 BP; 69 A; 128 C; 106 G; 87 T; 0 other;
Query Match	100.0%; Score 390; DB 22; Length 390;
Best Local Similarity	100.0%; Prod. No. 4.7e-102;
Matches 390; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
OY	1 ATGAAGCTGGCATTTCCTTCTTGAGGCCATGACCCCTCTCTGTGACTATGAC 60
Db	1 ATGAAGCTGGCATTTCCTTCTTGAGGCCATGACCCCTCTCTGTGACTATGAC 60
OY	61 TGTCGTCGCGCTCCAGTGGGAACCTGGCCACCCTTTGTGGGCTGTCCGTGAGGAG 120
Db	61 TGTCGTCGCGCTCCAGTGGGAACCTGGCCACCCTTTGTGGGCTGTCCGTGAGGAG 120
OY	121 TTACTTTCTTGCCCAAGAAGCCAGGCTGCAGGGGCTTCGGATCACACGATGCTGC 180
Db	121 TTACTTTCTTGCCCAAGAAGCCAGGCTGCAGGGGCTTCGGATCACACGATGCTGC 180
OY	181 TGGGTCGCTGTGAGAACCTGGGAGAAACCATTTCTGGAACCCCCTATATTGAAGCCAT 240
Db	181 TGGGTCGCTGTGAGAACCTGGGAGAAACCATTTCTGGAACCCCCTATATTGAAGCCAT 240
OY	241 CATCAGTCTGTACCTACACAAGAGACCAAGAGGTGACTGTCAAGTGGCCCAACTGTGCC 300
Db	241 CATCAGTCTGTACCTACACAAGAGACCAAGAGGTGACTGTCAAGTGGCCCAACTGTGCC 300
OY	301 CCGGAGTGTGACCCCTTCTTACACTATCCCGTGGCCATCCGCTGTGACTGCGAGAGCTTGC 360
Db	301 CCGGAGTGTGACCCCTTCTTACACTATCCCGTGGCCATCCGCTGTGACTGCGAGAGCTTGC 360
OY	361 TTCACCTGCCACACGAGAGTGTGAGACCATC 390
Db	361 TTCACCTGCCACACGAGAGTGTGAGACCATC 390
RESULT 2	
AAS17500	
ID	AAS17500 standard; cDNA. 390 BP.
XX	
AC	AAS17500;
XX	
DT	14-FEB-2002 (first entry)
XX	
DE	DNA encoding human beta-like glycoprotein hormone, Beta10.
XX	
KW	Human; glycoprotein hormone; beta10; homeostatic disorder; diabetes;
RW	stress response; immune system dysfunction; tissue damage; cancer;
KW	thyroid gland related condition; ss.
XX	
OS	Homo sapiens.
XX	
FH	Key
FT	sig_peptide
FT	/tag= a
FT	/tag= b
FT	/product= "Beta-like glycoprotein beta10"
FT	/partial
FT	/note= "No stop codon given"
FT	mat_peptide
FT	73..390

```

FT      /*tag= C
FT      /note= "Mature beta10"
FM
FN      WO200173034-A2.
XX
XX      04-OCT-2001.
XX
XX      28-MAR-2001; 2001WO-US09999.
XX
XX      28-MAR-2000; 2000US-19265AP.
XX      24-APR-2000; 2000US-199211P.
XX      27-NOV-2000; 2000US-0723970.
XX
XX      (AMGE-) AMGEN INC.
XX
XX      Paszty CJR, Cao J, Danilenko DM, Gong J, Hill DC;
XX      WPI; 2002-055150/07.
XX      P-PSDB; AAU10356.
XX
XX      New polynucleotides encoding polypeptides for treating and diagnosing
XX      disorders such as thyroid gland related conditions comprises novel
XX      human glycoprotein hormone polypeptide, and the beta10 protein -
XX
XX      Claim 1; Fig 1; 201pp; English.
XX
XX      The invention relates to an isolated polynucleotide (1) encoding
XX      beta-like glycoprotein polypeptide. The polynucleotides, polypeptides and
XX      heterodimers can be administered therapeutically (e.g. by administering
XX      the polynucleotides to modulate levels of beta10 polypeptide or
XX      heterodimer; to treat or prevent diseases and disorders such as
XX      homeostatic disorders (e.g. diabetes), disorders related to stress
XX      responses (e.g. immune system dysfunction) or disorders requiring
XX      increased cell differentiation/proliferation (e.g. tissue damage during
XX      cancer treatment). They can be included in compositions which are used
XX      for the same purposes. They are useful to diagnose pathological
XX      conditions or susceptibility to pathological conditions, especially
XX      thyroid gland related conditions. The polypeptides and heterodimers can
XX      be used to identify binding compounds. They are useful for producing
XX      antibodies, and for detecting or quantifying beta10 polypeptides,
XX      heterodimers, and selective binding agents. The polynucleotides can be
XX      used to produce cells comprising the polynucleotide, and for producing
XX      polypeptides/heterodimers and identifying compounds modulating beta 10
XX      polypeptide/heterodimer activity by detecting changes in activity or
XX      production in the cell. They can also be used to produce implantation
XX      devices to administer polypeptide/heterodimers. The present
XX      sequence represents the DNA encoding beta-like glycoprotein hormone
XX      beta10.
XX
XX      Sequence 390 BP; 69 A; 128 C; 106 G; 87 T; 0 other:
XX
XX      Query Match      100.0%; Score 390; DB 24; Length 390;
XX      Best Local Similarity 100.0%; Pred. No. 4.7e-102;
XX      Matches 390; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
XX
XX      1 ATGAAGCTGGCAATTCCTCTTCCCTGGCCCAATGGCCCTCTTGGCTGGCATATGAC 60
XX      1 ATGAAGCTGGCAATTCCTCTTCTTGGCCCAATGGCCCTCTTCTTGGCTGGCATATGAC 60
XX
XX      61 TGTGTCTCGTGGTGCCTCCAGTGGGAACCTGCGACCTTTGTGGGCTGTGCGTAGAGGAG 120
XX      61 TGTGTCTCGTGGTGCCTCCAGTGGGAACCTGCGACCTTTGTGGGCTGTGCGTAGAGGAG 120
XX
XX      61 TGTGTCTCGTGGTGCCTCCAGTGGGAACCTGCGACCTTTGTGGGCTGTGCGTAGAGGAG 120
XX      61 TGTGTCTCGTGGTGCCTCCAGTGGGAACCTGCGACCTTTGTGGGCTGTGCGTAGAGGAG 120
XX
XX      121 TTACTTCTTCGCGCAAGAAGCCAGGCTGCAGAGGCGCTTGGATACACAGGATGCTGC 180
XX      121 TTACTTCTTCGCGCAAGAAGCCAGGCTGCAGAGGCGCTTGGATACACAGGATGCTGC 180
XX
XX      121 TTACTTCTTCGCGCAAGAAGCCAGGCTGCAGAGGCGCTTGGATACACAGGATGCTGC 180
XX      121 TTACTTCTTCGCGCAAGAAGCCAGGCTGCAGAGGCGCTTGGATACACAGGATGCTGC 180
XX
XX      181 TGGGCTCGCTGTGAGACCTGGAGAAACCCATTCTGGAACCCGCCCTATTTAAGCCCAT 240
XX      181 TGGGCTCGCTGTGAGACCTGGAGAAACCCATTCTGGAACCCGCCCTATTTAAGCCCAT 240
XX
XX      181 TGGGCTCGCTGTGAGACCTGGAGAAACCCATTCTGGAACCCGCCCTATTTAAGCCCAT 240
XX      181 TGGGCTCGCTGTGAGACCTGGAGAAACCCATTCTGGAACCCGCCCTATTTAAGCCCAT 240
XX
XX      241 CATGAGTCTGTACTACAGAGAACCAAGGTGACTGTCAAGCTGCCCAACTGTGCC 300
XX      241 CATGAGTCTGTACTACAGAGAACCAAGGTGACTGTCAAGCTGCCCAACTGTGCC 300

```

```
Db 241 CATGAGTCTGTACTTACACAAACGAGACCAACAGGAGTGTGACGTCGACGTCGCCACTGTGCC 300
QY 301 CCGGAGTGCACCCCTTCTTACACCTATCCGTCGCTGACTGCGGAGCCTGC 360
Db 301 CCGGAGTGCACCCCTTCTTACACCTATCCGTCGCTGACTGCGGAGCCTGC 360
QY 361 TCCACTGCCACGAGGAGTGTGAGACCATC 390
Db 361 TCCACTGCCACGAGGAGTGTGAGACCATC 390

RESULT 3
AADI6347
ID AADI6347 standard; DNA: 393 BP.
AC AADI6347;
XX 19-NOV-2001 (first entry)
DE Human sbhgta gene.
XX
KW Human; Alzheimer's disease; amyotrophic lateral sclerosis;
KW ALS; Zollinger-Elison syndrome; immune system disease; schizophrenia;
KW inflammation; haematopoietic disease; anxiety; feeding disorder; aging;
KW anorexia; depression; cardiovascular disease; sleep disorder; seizure;
KW memory alteration; migraine; stroke; asthma; neuropathy; hypoglycaemia;
KW sexual disorder; growth abnormality; infection; autoimmune disease;
KW rheumatoid arthritis; cataractogenesis; angiogenesis; atherosclerosis;
KW cerebral ischaemia; cirrhosis; Huntington's disease; Hodgson's disease;
KW hypercholesterolaemia; headache; amnesia; cardiac arrhythmia; obesity;
KW diabetes mellitus; glomerulonephritis; renovascular hypertension;
KW cancer; vaccine; gene therapy; sbhgta gene; ds.
XX
OS Homo sapiens.
XX
FH Key 1..393 Location/Qualifiers
FT CDS /*tag= a
FT /product= "Human sbhgta protein"
XX
PN WO200160850-A1.
XX
PD 23-AUG-2001.
XX
PF 14-FEB-2001; 2001WO-US04703.
XX
PR 14-FEB-2000; 2000US-0182172.
PR 29-FEB-2000; 2000US-0186084.
PR 18-APR-2000; 2000US-0198583.
PR 04-OCT-2000; 2000US-0237963.
XX
PA (SMIK ) SMITHKLINE BEECHAM CORP.
PA (SMIK ) SMITHKLINE BEECHAM PLC.
XX
PI Agarwal P, Kabnick KS, Murdoch PR, Rizvi SK, Smith RF, Xiang Z;
XX WPI: 2001-536566/59.
XX DR P-PSDB; AA09440.
XX
PT New secreted and membrane associated polypeptides for treating
PT Alzheimer's disease, psoriasis, cancer, enterocolitis, sleep and sexual
PT disorders, stroke, and asthma
XX
PS Claim 2; Page 38; 94pp; English.
XX
XX The present sequence is a gene encoding human sbhgta protein,
XX a secreted protein of the invention.
XX CC The invention relates to secreted and membrane associated polypeptides
XX and nucleic acid molecules encoding such polypeptides. Sequences of the
XX invention are useful for treating diseases such as Alzheimer's disease,
XX amyotrophic lateral sclerosis (ALS), Zollinger-Elison syndrome, diseases
XX of the immune system, haematopoietic disease, inflammation, anxiety,
XX schizophrenia, feeding disorders, anorexia, depression, social, sexual
```

```
CC and rewarded behaviour, cardiovascular disease, sleep disorder, learning
CC and memory alteration and altered immune response, seizure, migraine,
CC cancer, stroke, asthma, neuropathy, aging, sexual disorders, treatment
CC of transsexuals, growth abnormalities, obesity, infections, autoimmune
CC diseases (e.g. rheumatoid arthritis), cataractogenesis, angiogenesis,
CC disorders associated with healthy maintenance of gastric mucosa and
CC repair of acute and chronic mucosal lesion, lung carcinoma, cerebral
CC ischaemia, atherosclerosis, cirrhosis, Huntington's disease, headache,
CC amnesia, multiple sclerosis, Hodgson's disease, dilated cardiomyopathy,
CC congestive heart failure, cardiac arrhythmias, hypercholesterolaemia,
CC viral and non-viral hepatitis, type I and type II diabetes mellitus,
CC glomerulonephritis, renovascular hypertension, hypoglycaemia, periodic
CC paralyseis, tendinitis and malignant hyperthermia. Polypeptides of the
CC invention are used to identify membrane bound and soluble receptors.
CC They are also useful as vaccines for inducing an immunological response
CC in a mammal. Polynucleotides of the invention are used in gene therapy.
CC They are also valuable for chromosome localisation studies and tissue
CC expression studies.
XX
SO Sequence 393 BP; 70 A; 128 C; 107 G; 88 T; 0 other;
Query Match 100.0%; Score 390; DB 22; Length 393;
Best Local Similarity 100.0%; Pred. No. 4, 7e-102;
Matches 390; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ATGAGCTGGCATTCCTCTTGGCCCATGGCCCTCCCTCTGCTGCTGCTATGAGC 60
Db 1 ATGAGCTGGCATTCCTCTTGGCCCATGGCCCTCCCTCTGCTGCTGCTATGAGC 60
QY 61 TGTGCTCTGCGGCTCCAGTGGAGAACCTGCTTGTGGCTGTGCTGAGGAG 120
Db 61 TGTGCTCTGCGGCTCCAGTGGAGAACCTGCTTGTGGCTGTGCTGAGGAG 120
QY 121 TTTACTTTCCTGGCCAGAGCCAGGCTGACGGGCTTGGATACCAAGATCCCTGC 180
Db 121 TTTACTTTCCTGGCCAGAGCCAGGCTGACGGGCTTGGATACCAAGATCCCTGC 180
QY 181 TGGGTCCTGTGAGACCTGGGAGAAACCATTCCTGGAAACCCCTATATTGAACCCAT 240
Db 181 TGGGTCCTGTGAGACCTGGGAGAAACCATTCCTGGAAACCCCTATATTGAACCCAT 240
QY 241 CATGAGTCTGTACTTACACGAGACCAACAGTGTGACTGTCAAGCTGCCAAGTGTGC 300
Db 241 CATGAGTCTGTACTTACACGAGACCAACAGTGTGACTGTCAAGCTGCCAAGTGTGC 300
QY 301 CCGGAGTGCACCCCTTCTTACACCTATCCCGTGGCATCCGCTGTGACTGCGGAGCCTGC 360
Db 301 CCGGAGTGCACCCCTTCTTACACCTATCCCGTGGCATCCGCTGTGACTGCGGAGCCTGC 360
QY 361 TCCACTGCCACGAGGAGTGTGAGACCATC 390
Db 361 TCCACTGCCACGAGGAGTGTGAGACCATC 390

RESULT 4
AAH42567
ID AAH42567 standard; DNA: 917 BP.
XX
XX AAH42567;
AC AAH42567;
XX
XX 01-OCT-2001 (first entry)
DE Nucleotide sequence of a human cystine knot polypeptide.
XX
XX Cysteine knot polypeptide; follicular arrest; recruitment modulator;
KW fertility-related disorder; contraception; menopause; contraceptive;
KW follicle growth; ss.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX FT 101..493
XX CDS /*tag= a
```

```

XX      /product= "cystine knot polypeptide"
XX      WO200153346-A1.
XX      26-JUL-2001.
XX      17-JAN-2001; 2001WO-EP00570.
XX      18-JAN-2000; 2000EP-0200185.
XX      (ALKU ) AKZO NOBEL NV.
XX      Mosseiman S, Spek Van Der PJ;
XX      WPI: 2001-476102/51.
XX      P-PSDB; AAG63211.
XX
XX      New DNA sequences, useful for coding or producing cystine knot
XX      polypeptides, which are useful in preparing a pharmaceutical for
XX      fertility-related disorders or contraception, and for controlling
XX      follicular arrest and recruitment.
XX
XX      Claim 6; Page 23; 29pp; English.
XX
XX      The present sequence encodes a human cystine knot polypeptide. The
XX      polypeptide is a follicular arrest and recruitment modulator. Cystine
XX      knot polypeptides are useful in preparing a pharmaceutical for
XX      fertility-related disorders or in contraception. The polypeptide is
XX      particularly useful for controlling follicular arrest and recruitment.
XX      Inhibition of recruitment can be used to delay (premature) menopause or
XX      as a contraceptive. The polypeptide is also useful for in vitro
XX      maturation and growth of follicles, e.g. from frozen ovarian tissue.
XX
XX      Sequence 917 BP; 222 A; 249 C; 205 G; 241 T; 0 other;
XX
XX      Query Match      100.0%; Score 390; DB 22; Length 917;
XX      Best Local Similarity 100.0%; Pred. No. 6,1e-102;
XX      Matches 390; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX      1 ATGAAGCTGGCATTCCTCTTGGGCCCATGGCCCTCTCTTGGCTGATGAGC 60
XX      101 ATGAAGCTGGCATTCCTCTTGGGCCCATGGCCCTCTCTTGGCTGATGAGC 160
XX      61 TGTGCTCTGCGCTCTTGCAGTGGGAACCTTGTGGGCTGTGCGTGAGGAG 120
XX      161 TGTGCTCTGCGCTCTTGCAGTGGGAACCTTGTGGGCTGTGCGTGAGGAG 220
XX      121 TTACTCTTCTGGCAAGAACGAGGCTGAGGGCTTGGATACACGAGATGCTGC 180
XX      221 TTACTCTTCTGGCAAGAACGAGGCTGAGGGCTTGGATACACGAGATGCTGC 280
XX      181 TGGGCTGCTGTGAGACCTTGGAGAAACCATTCGTAACCCCTATATTGAAGCCAT 240
XX      281 TGGGCTGCTGTGAGACCTTGGAGAAACCATTCGTAACCCCTATATTGAAGCCAT 340
XX      241 CATGAGTGTGTAACCTTGAACAGAGACCAACAGAGTGAAGTGCCTGAGCC 300
XX      341 CATGAGTGTGTAACCTTGAACAGAGACCAACAGAGTGAAGTGCCTGAGCC 400
XX      301 CGGGAGTGGACCCCTTCTACCTATCCGTCGTCGCTGAGTGCCTGAGCC 360
XX      401 CGGGAGTGGACCCCTTCTACCTATCCGTCGTCGCTGAGTGCCTGAGCC 460
XX      361 TCCACTGCCACACGAGAGTGTGAGACCATC 390
XX      461 TCCACTGCCACACGAGAGTGTGAGACCATC 490
XX
XX      RESULT 5
XX      AAF83867
XX      ID AAF83867 standard; cDNA; 693 BP.
XX      AAF83867;
XX
```

```

XX      06-AUG-2001 (first entry)
XX      Human novel gonadotropin (NOVGON) protein encoding cDNA.
XX
XX      NOVG, transmembrane protein; NOVTRAN; neuromedin peptide; NOVNEUR;
XX      gonadotropin-like protein; NOVGON; interleukin-1; NOVINTRA; human;
XX      cytosolic; neuroprotective; reproductive; antiinflammatory; cancer;
XX      antibacterial; cerebroprotective; antidiabetic; antiarthritic;
XX      antiallergic; ss.
XX
XX      Homo sapiens.
XX
XX      Key      Location/Qualifiers
XX      CDS      1..693
XX      FT      /tag= a
XX      FT      /product= "NOVGON"
XX
XX      WO200140291-A2.
XX      PD      07-JUN-2001.
XX
XX      06-DEC-2000; 2000WO-US33029.
XX      PF      06-DEC-1999; 99US-0169056.
XX      PR      09-DEC-1999; 99US-0169866.
XX      PR      09-DEC-1999; 99US-0169866.
XX      PR      10-DEC-1999; 99US-0170252.
XX      PR      12-JAN-2000; 2000US-0175740.
XX      PR      05-DEC-2000; 2000US-0170252.
XX
XX      (CURA-) CURAGEN CORP.
XX
XX      Burgess CE, Prayaga SK, Shimkets RA, Rastelli L, Zerhusen BD;
XX      Mezes PS.
XX      WPI: 2001-374790/39.
XX      P-PSDB; AAB84998.
XX
XX      Novel isolated human transmembrane, neuromedin peptide
XX      gonadotropin-like protein and interleukin-1 receptor antagonist
XX      proteins, useful for treating cancer, immune response disorder,
XX      metabolic function disorders.
XX
XX      Claim 8; Fig 6A; 138pp; English.
XX
XX      The invention provides novel polypeptides (NOVG) selected from human
XX      transmembrane protein (NOVTRAN), neuromedin peptide (NOVNEUR),
XX      gonadotropin-like protein (NOVGON) and two interleukin-1 receptor
XX      antagonist proteins (NOVINTRA A and B). The invention also provides
XX      methods in which a NOVG polypeptide, polynucleotide and antibody are
XX      used in the detection, prevention and treatment of a broad range of
XX      pathological states. NOVTRAN can be used to treat a cell signaling
XX      disorder such as cancer, immune response disorder, hematopoietic
XX      disorder, neurodegenerative disorder. NOVNEUR can be used to treat
XX      endocrine disorder, muscle disorder, neurologic disorder, cancers of
XX      central nervous system, breast, colon, ovary, kidney, prostate and
XX      thyroid. NOVGON can be used to treat reproductive development disorder,
XX      metabolic function disorder and melanoma. NOVINTRA A and B can be used
XX      to treat bone metabolism or structure disorder, inflammatory response
XX      disorder, immune regulation disorder, septic shock, stroke, diabetes,
XX      arthritis and cancer. The present sequence represents a cDNA encoding
XX      the NOVGON polypeptide.
XX
XX      Sequence 693 BP; 138 A; 197 C; 196 G; 162 T; 0 other;
XX
XX      Query Match      96.9%; Score 378; DB 22; Length 693;
XX      Best Local Similarity 100.0%; Pred. No. 1.5e-98;
XX      Matches 378; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX      1 ATGAAGCTGGCATTCCTCTTGGGCCCATGGCCCTCTCTTGGCTGATGAGC 60
XX      1 ATGAAGCTGGCATTCCTCTTGGGCCCATGGCCCTCTCTTGGCTGATGAGC 60
XX
```

QY 61 TGTGTCTCTGCTGCTCCAGTGGGAGACCTGCGACCTTTGTGGGCTGTGCCGTGAGGGAG 120
Db 61 TGTGTCTCTGCTGCTCCAGTGGGAGACCTGCGACCTTTGTGGGCTGTGCCGTGAGGGAG 120
QY 121 TTTACTTCTCTGCGCAAGAACCCAGGCTGCGAGGGCTTGGATCACCACGATGCTGCG 180
Db 121 TTTACTTCTCTGCGCAAGAACCCAGGCTGCGAGGGCTTGGATCACCACGATGCTGCG 180
QY 181 TGGGGTCTGTGTGAGACCTGGGAGAAACCAATTCGTGAACCCCTATATTGAAGCCCAT 240
Db 181 TGGGGTCTGTGTGAGACCTGGGAGAAACCAATTCGTGAACCCCTATATTGAAGCCCAT 240
QY 241 CATGAGTCTGTACTTACACAGAGAACCAAGAGTGTGACTGTCAAGCTGCCACTGTGCC 300
Db 241 CATGAGTCTGTACTTACACAGAGAACCAAGAGTGTGACTGTCAAGCTGCCACTGTGCC 300
QY 301 CCGGAGTCTGACCCCTTCTACACCTATCCGCTGCGCATCCGCTGTGACTGTGAGAGCTGCG 360
Db 301 CCGGAGTCTGACCCCTTCTACACCTATCCGCTGCGCATCCGCTGTGACTGTGAGAGCTGCG 360
QY 361 TCCACTGCCACACGAG 378
Db 361 TCCACTGCCACACGAG 378

RESULT 6
AAH46589
ID AAH46589 standard; DNA: 318 BP.

AC AAH46589;

DT 17-SEP-2001 (first entry)

DE Human anterior pituitary hormone-related polynucleotide #2.

XX Human: anterior pituitary hormone; hypertension; autoimmune disease;

XX heart failure; ds.

OS Homo sapiens.

PN WO200144475-A1.

PD 21-JUN-2001.

PF 15-DEC-2000; 2000WO-JP08896.

PR 17-DEC-1999; 99JP-0358707.

PR 18-FEB-2000; 2000JP-0046825.

PA (TAKE) TAKEDA CHEM IND LTD.

PI Hinuma S, Fukusumi S, Fujii R, Hosoya M;

DR WPI: 2001-408485/43.

PT P-PSDB; AAG64065.

PT Polypeptides for treatment of hypertension, autoimmune disease and

PT heart failure .

PS Claim 7; Page 100-101; 107pp; Japanese.

XX The invention relates to a novel polypeptide comprising a fully defined

CC 130 amino acid sequence given in the specification and its amides,

CC esters and salts. The polypeptide has anterior pituitary hormone-related

CC activity. It is useful for the treatment of hypertension, autoimmune

CC diseases and heart failure. The screening method and kit also

CC provided in the invention are useful for identifying new substances

CC for treating and preventing these diseases. The present sequence

CC encodes a polypeptide of the invention.

XX Sequence 318 BP: 63 A; 103 C; 88 G; 64 T; 0 other;

Query Match 81.5%; Score 318; DB 22; Length 318;
Best Local Similarity 100.0%; Pred. No. 1.8e-81;
Matches 318; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 73 GCTTCAGTGGGAACCTTCGACACCTTTGTGGCTGTGCTGAGAGATTTACTTCTCG 132
Db 1 GCTTCAGTGGGAACCTTCGACACCTTTGTGGCTGTGCTGAGAGATTTACTTCTCG 60
QY 133 GCCAAGAACCCAGGCTGAGGGCTTGGATCACCACGATGCTGCTGGGCTGCTGT 192
Db 61 GCCAAGAACCCAGGCTGAGGGCTTGGATCACCACGATGCTGCTGGGCTGCTGT 120
QY 193 GAGACCTGGGAAACCATTCGTGAACCCCTATATTGAAGCCCATCATGAGTCTGT 252
Db 121 GAGACCTGGGAAACCATTCGTGAACCCCTATATTGAAGCCCATCATGAGTCTGT 180
QY 253 ACCTACACAGAGACCAACAGAGTGTCAAGCTGACCTGCCACTGTGCCGAGTCTGAC 312
Db 181 ACCTACACAGAGACCAACAGAGTGTCAAGCTGACCTGCCACTGTGCCGAGTCTGAC 240
QY 313 CCTTTCTACCTTATCCGCTGCGCATTCGCTGTGACTGCGAGCTGCTCCACTGCCACC 372
Db 241 CCTTTCTACCTTATCCGCTGCGCATTCGCTGTGACTGCGAGCTGCTCCACTGCCACC 300
QY 373 ACGAGTGTGAGACCATC 390
Db 301 ACGAGTGTGAGACCATC 318

RESULT 7
AAAS17508
ID AAAS17508 standard; cDNA: 393 BP.

AC AAAS17508;

DT 14-FEB-2002 (first entry)

DE DNA encoding mouse beta-like glycoprotein hormone, Beta10.

XX Mouse; glycoprotein hormone; beta10; homeostatic disorder; diabetes;

XX stress response; immune system dysfunction; tissue damage; cancer;

XX thyroid gland related condition; ss.

OS Mus musculus.

XX Key Location/Qualifiers

FT sig_peptide 1..69

FT CDS 1..393

FT /*tag= b

FT /product= "Beta-like glycoprotein beta10"

FT /*tag= c

FT /note= "Mature beta10"

PN WO200173034-A2.

PD 04-OCT-2001.

PF 28-MAR-2001; 2001WO-US09999.

PR 28-MAR-2000; 2000US-192654P.

PR 24-APR-2000; 2000US-199211P.

PR 27-NOV-2000; 2000US-0723970.

PA (AMGE-) AMGEN INC.

XX Paszty CJR, Cao J, Danilenko DM, Gong J, Hill DC;

DR WPI: 2002-055150/07.

DR P-PSDB; AAU10368.

XX New polynucleotides encoding polypeptides for treating and diagnosing

PT disorders such as thyroid gland related conditions comprises novel
PT human glycoprotein hormone polypeptide, and the beta10 protein -
XX
XX
PS Example 5; Page 194; 201pp; English.

CC The invention relates to an isolated polynucleotide (1) encoding
CC beta-like glycoprotein polypeptide. The polynucleotides, polypeptides and
CC heterodimers can be administered therapeutically (e.g. by administering
CC the polynucleotides to modulate levels of beta10 polypeptide or
CC heterodimer; to treat or prevent diseases and disorders such as
CC homeostatic disorders (e.g. diabetes), disorders related to stress
CC responses (e.g. immune system dysfunction) or disorders requiring
CC increased cell differentiation/proliferation (e.g. tissue damage during
CC cancer treatment). They can be included in compositions which are used
CC for the same purposes. They are useful to diagnose pathological
CC conditions or susceptibility to pathological conditions, especially
CC thyroid gland related conditions. The polypeptides and heterodimers can
CC be used to identify binding compounds. They are useful for producing
CC antibodies, and for detecting or quantifying beta10 polypeptides,
CC heterodimers, and selective binding agents. The polynucleotides can be
CC used to produce cells comprising the polynucleotide, and for producing
CC polypeptides/heterodimers and identifying compounds modulating beta 10
CC polypeptide/heterodimer activity by detecting changes in activity or
CC production in the cell. They can also be used to produce implantation
CC devices to administer polypeptide/heterodimers. The present
CC sequence represents the DNA encoding mouse beta-like glycoprotein hormone
CC beta10.
CC
XX
SQ Sequence 393 BP; 78 A; 111 C; 109 G; 95 T; 0 other;

Query Match

Best Local Similarity 77.0%; Score 300.4; DB 24; Length 393;
Matches 334; Conservative 0; Mismatches 56; Indels 0; Gaps 0;

QY 1 ATGAAGCTGGCATTTCTCTTCTGGCCCATGGCCCTCTCTGCTGCTATGCG 60
DB 1 ATGAAGTTGGTATACCTTGTCTCTGTCAGTGGCCCTCTCTGCTGCTATGCG 60
QY 61 TGTGTCCTCGGTGCTCCAGTGGGAACCTGCGACCTTTGTGGCTGTGCGTGAAGGAG 120
DB 61 TGTGTCCTCGAGCTCCAGTGGGAACCTGCGACCTTTGTGGCTGTGCGTGAAGGAG 120
QY 121 TTACTCTTCTGGCCAAAGACCGAGCTGAGGGCTTCGATCAACAGATGCTCG 180
DB 121 TTACTCTTCTGGCCAAAGACCGAGCTGAGGGCTTCGATCAACAGATGCTCG 180
QY 181 TGGGTCGCTGAGAGCTGGAGAAACCATTTCTGAAACCCCTATATTGAAGCCAT 240
DB 181 TGGGTCGCTGAGAGCTGGAGAAACCATTTCTGAAACCCCTATATTGAAGCCAT 240
QY 241 CATCGAGTGTACTACACAGACCAAGAGTACTGTCAAGTCCCAACTGTGCC 300
DB 241 CATCGAGTGTACTACACAGACCAAGAGTACTGTCAAGTCCCAACTGTGCC 300
QY 301 CGGGAGTGGAGCCCTTCTACACCTATCCCGTGGCCATCCGCTGATGCGGAGCTCG 360
DB 301 CGGGAGTGGAGCCCTTCTACACCTATCCCGTGGCCATCCGCTGATGCGGAGCTCG 360
QY 361 TCCACTGCGACCAAGAGTGTGAGACCATC 390
DB 361 TCCACTGCGACCAAGAGTGTGAGACCATC 390

RESULT 8

AAH46593

ID AAH46593 standard; DNA; 387 BP.

AC AAH46593;

XX 17-SEP-2001 (first entry)

XX Rat anterior pituitary hormone-related polynucleotide #1.

KW Rat; anterior pituitary hormone; hypertension; autoimmune disease;
KW heart failure; ds.
XX
XX
OS Rattus sp.
XX
PN WO200144475-A1.
XX
XX 21-JUN-2001.
PD
XX
PF 15-DEC-2000; 2000MO-JP08896.
XX
XX 17-DEC-1999; 99JP-0358707.
PR 18-FEB-2000; 2000JP-0046825.
XX
PA (TAKE) TAKEDA CHEM IND LTD.

PI Hinuma S, Fukusumi S, Fujii R, Hosoya M;
XX
XX WPI; 2001-408485/43.
DR P-PSDB; AAG64067.
XX
XX
PT Polypeptides for treatment of hypertension, autoimmune disease and
XX heart failure -
XX
PS Claim 7; Page 103; 107pp; Japanese.

CC The invention relates to a novel polypeptide comprising a fully defined
CC 130 amino acid sequence given in the specification and its amides,
CC esters and salts. The polypeptide has anterior pituitary hormone-related
CC activity. It is useful for the treatment of hypertension, autoimmune
CC diseases and heart failure. The screening method and kit also
CC provided in the invention are useful for identifying new substances
CC for treating and preventing these diseases. The present sequence is
CC is a polynucleotide encoding a polypeptide provided in the specification.
XX
SQ Sequence 387 BP; 77 A; 110 C; 108 G; 92 T; 0 other;

Query Match

Best Local Similarity 74.6%; Score 290.8; DB 22; Length 387;
Matches 335; Conservative 0; Mismatches 52; Indels 3; Gaps 1;

QY 1 ATGAAGCTGGCATTTCTCTTCTGGCCCATGGCCCTCTCTGCTGCTATGCG 60
DB 1 ATGAAGCTGGTATACCTTGTCTCTGTCAGTGGCCCTCTCTGCTGCTATGCG 57
QY 61 TGTGTCCTCGGTGCTCCAGTGGGAACCTGCGACCTTTGTGGCTGTGCGTGAAGGAG 120
DB 58 TGTGTCCTCGAGCTCCAGCGGGAACCTGCGACCTTTGTGGCTGTGCGTGAAGGAG 117
QY 121 TTACTCTTCTGGCCAAAGACCGAGCTGAGGGCTTCGATCAACAGATGCTCG 180
DB 118 TTACTCTTCTGGCCAAAGACCGAGCTGAGGGCTTCGATCAACAGATGCTCG 177
QY 181 TGGGTCGCTGAGAGCTGGAGAAACCATTTCTGAAACCCCTATATTGAAGCCAT 240
DB 178 TGGGTCGCTGAGAGCTGGAGAAACCATTTCTGAAACCCCTATATTGAAGCCAT 237
QY 241 CATCGAGTGTACTACACAGACCAAGAGTACTGTCAAGTCCCAACTGTGCC 300
DB 238 CATCGAGTGTACTACACAGACCAAGAGTACTGTCAAGTCCCAACTGTGCC 297
QY 301 CGGGAGTGGAGCCCTTCTACACCTATCCCGTGGCCATCCGCTGATGCGGAGCTCG 360
DB 298 CGGGAGTGGAGCCCTTCTACACCTATCCCGTGGCCATCCGCTGATGCGGAGCTCG 357
QY 361 TCCACTGCGACCAAGAGTGTGAGACCATC 390
DB 358 TCCACTGCGACCAAGAGTGTGAGACCATC 387

RESULT 9

AAH46594

ID AAH46594 standard; DNA; 318 BP.

```

XX AAH46594;
AC 17-SEP-2001 (first entry)
DT
XX Rat anterior pituitary hormone-related polynucleotide #2.
XX Rat: anterior pituitary hormone; hypertension; autoimmune disease:
XX heart failure; ds.
XX Rattus sp.
XX WO200144475-A1.
XX 21-JUN-2001.
XX 15-DEC-2000; 2000WO-JP08896.
XX 17-DEC-1999; 99JP-0358707.
XX 18-FEB-2000; 2000JP-0046825.
XX (TAKE ) TAKEDA CHEM IND LTD.
XX Hinuma S, Fukusumi S, Fujii R, Hosoya M;
XX WPI: 2001-408485/43.
XX P-PSDB; AAG64068.
XX Polypeptides for treatment of hypertension, autoimmune disease and
XX heart failure -
XX Claim 7; Page 104; 107pp; Japanese.
XX The invention relates to a novel polypeptide comprising a fully defined
XX 130 amino acid sequence given in the specification and its amides,
XX esters and salts. The polypeptide has anterior pituitary hormone-related
XX activity. It is useful for the treatment of hypertension, autoimmune
XX diseases and heart failure. The screening method and kit also
XX provided in the invention are useful for identifying new substances
XX for treating and preventing these diseases. The present sequence is
XX a polynucleotide encoding a polypeptide provided in the specification.
XX
XX Sequence 318 BP; 69 A; 89 C; 90 G; 70 T; 0 other:
XX
XX Query Match 66.7%; Score 260; DB 22; Length 318;
XX Best Local Similarity 88.9%; Pred. No. 7.2e-65;
XX Matches 281; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
XX
XX 75 CTCGAGTGGGACCTGGACCTTTGTGGGCTGTGGCGTGGAGGAGTTTACTTTCTGGGC 134
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX 3 CTCGAGGCGGACCTACACACTTTTGTGGATGTGCTGTGAGGAATTCACCTTTTGTGGC 62
XX
XX 135 CAAGAAAGCCAGGCTGCAGGGGCTTCGGATCACCACGGAATGCTGTGGGCTCGCTGTGA 194
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX 63 CAAGAAAGCCAGGCTGCAGGGGCTTCGGATCACCACAGATGCCGTGGGCTCGCTGTGA 122
XX
XX 195 GACCTGGGAAAGAACCTTTGTGAACCCCTTATTTGAAGCCATATGAGCTGTAC 254
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX 123 GACCTGGGAAAGAACCTTTGTGAACCTTCCTACATGAAAGCCATATGAGCTGTAC 182
XX
XX 255 CTCACAGAGACCAAGAGCTGACCTGCAAGCTGCCAAGCTGCCCCGGAGTGCAGCC 314
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX 183 CTCACAGAGACCAAGAGGCTGACGCTGAAAGCTGCTAAGTGTCCCTGGAGTGCAGCC 242
XX
XX 315 CTCCTACACCTATTCCTGCGCATCGCTGTGATGCGGAGCCGTGCTCCATGCGCACAC 374
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX 243 CTCCTACACCTACCTATGCTGTGCGATGTGATGCGGGGCAATGTTCACATGCCACAC 302
XX
XX 375 GGAGTGGAGACCATC 390
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX 303 TGAATGTGAGACCATC 318

```

```

RESULT 10
AAH42568
ID AAH42568 standard; DNA: 1045 BP.
XX
XX AC AAH42568;
XX
XX 01-OCT-2001 (first entry)
XX
XX Nucleotide sequence of human cystine knot polypeptide splice variant.
XX
XX Cystine knot polypeptide; follicular arrest; recruitment modulator;
XX fertility-related disorder; contraception; menopause; contraceptive;
XX follicle growth; ss.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX CDS 101..328
XX FT /*tag= a
XX FT /product= "cystine knot polypeptide"
XX
XX WO200153346-A1.
XX
XX 26-JUL-2001.
XX
XX 17-JAN-2001; 2001WO-EP00570.
XX
XX 18-JAN-2000; 2000EP-0200185.
XX
XX (ALKU ) AKZO NOBEL NV.
XX
XX Mosselman S, Spek Van Der PJ;
XX
XX WPI: 2001-476102/51.
XX P-PSDB; AAG63212.
XX
XX New DNA sequences, useful for coding or producing cystine knot
XX polypeptides, which are useful in preparing a pharmaceutical for
XX fertility-related disorders or contraception, and for controlling
XX follicular arrest and recruitment -
XX
XX Claim 7; Page 24; 29pp; English.
XX
XX The present sequence encodes a human cystine knot polypeptide splice
XX variant. The polypeptide is a follicular arrest and recruitment
XX modulator. Cystine knot polypeptides are useful in preparing a
XX pharmaceutical for fertility-related disorders or in contraception.
XX The polypeptide is particularly useful for controlling follicular
XX arrest and recruitment. Inhibition of recruitment can be used to delay
XX (premature) menopause or as a contraceptive. The polypeptide is also
XX useful for in vitro maturation and growth of follicles, e.g. from
XX frozen ovarian tissue.
XX
XX Sequence 1045 BP; 254 A; 279 C; 234 G; 278 T; 0 other:
XX
XX Query Match 64.6%; Score 252; DB 22; Length 1045;
XX Best Local Similarity 75.3%; Pred. No. 2e-62;
XX Matches 390; Conservative 0; Mismatches 35; Indels 128; Gaps 1;
XX
XX 1 ATGAAGCTGCGATTCCTCTTGGCCCATGGCCCTCTCTTGGCTGGCTATGCG 60
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX 101 ATGAAGCTGCGATTCCTCTTGGCCCATGGCCCTCTCTTGGCTGGCTATGCG 160
XX
XX 61 TGTGTCTCGGTGCTCCAGTGGGAACCTGTGGGCTGTGCGGTAGAGAG 120
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX 161 TGTGTCTCGGTGCTCCAGTGGGAACCTGTGGGCTGTGCGGTAGAGAG 220
XX
XX 121 TTTACTTTCTGGCCAGGAAGCGGCTGCGAGGGGCTTGGATCACCAGGATGCGTC 180
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX 221 TTTACTTTCTGGCCAGGAAGCGGCTGCGAGGGGCTTGGATCACCAGGATGCGTC 280
XX
XX 181 TGGGCTGCTGTGAGACCTGGAG----- 204
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

```

DB 281 TGGGGTCCGTGACACCTGGAGCTTTTGTCAAGATGTCGTGTATGAACAAGGCATTCA 340
QY 205 ----- 204
DB 341 AATACATTTGTTGTTGACTGGATGGAACCTCCCGTGGAGCTGTAGATCTCCAGCC 400
QY 205 -----AACCATTCTGGAAACCCCTATATTG 232
DB 401 AATGGAAGCCATTAGAAATCACACTTGCACCTAAACCATTCTGGAAACCCCTATATTG 460
QY 233 AAGCCATCATGAGTCTGACTACACAGACCAACAGAGTCAAGCTGCCCCA 292
DB 461 AAGCCATCATGAGTCTGACTACACAGACCAACAGAGTCAAGCTGCCCCA 520
QY 293 ACTGTGCCCCGGAGTGCAGACCCCTTCTACACCTATCCGTTGGCCATCCGCTGTACTGCG 352
DB 521 ACTGTGCCCCGGAGTGCAGACCCCTTCTACACCTATCCGTTGGCCATCCGCTGTACTGCG 580
QY 353 GAGCCTGCTCCACTGCGACACGAGGTGAGACCATC 390
DB 581 GAGCCTGCTCCACTGCGACACGAGGTGAGACCATC 618

RESULT 11

AA517518
ID AAS17518 standard; DNA; 2985 BP.
XX AAS17518;
AC
XX
DT 14-FEB-2002 (first entry)

DE Genomic DNA encoding mouse beta-like glycoprotein hormone, beta10.

KM Mouse; glycoprotein hormone; beta10; homeostatic disorder; diabetes;
KM stress response; immune system dysfunction; tissue damage; cancer;
KM thyroid gland related condition; ds.

XX Mus musculus.

XX WO200173034-A2.

XX 04-OCT-2001.

XX 28-MAR-2001; 2001WO-US09999.

XX 28-MAR-2000; 2000US-192654P.

XX 24-APR-2000; 2000US-199211P.

XX 27-NOV-2000; 2000US-0723970.

XX (AMGE-) AMGEN INC.

XX Paszty CJR, Cao J, Danilenko DM, Gong J, Hill DC;

XX WPI: 2002-055150/07.

XX New polynucleotides encoding polypeptides for treating and diagnosing

XX disorders such as thyroid gland related conditions comprises novel

XX human glycoprotein hormone polypeptide, and the beta10 protein -

XX Example 6; Page 198-199; 201pp; English.

XX The invention relates to an isolated polynucleotide (1) encoding

XX beta-like glycoprotein polypeptide. The polynucleotides, polypeptides and

XX heterodimers can be administered therapeutically (e.g. by administering

XX the polynucleotides to modulate levels of beta10 polypeptide or

XX heterodimer; to treat or prevent diseases and disorders such as

XX homeostatic disorders (e.g. diabetes), disorders related to stress

XX responses (e.g. immune system dysfunction) or disorders requiring

XX increased cell differentiation/proliferation (e.g. tissue damage during

XX cancer treatment). They can be included in compositions which are used

XX for the same purposes. They are useful to diagnose pathological

XX conditions or susceptibility to pathological conditions, especially

XX thyroid gland related conditions. The polypeptides and heterodimers can

CC be used to identify binding compounds. They are useful for producing
CC antibodies, and for detecting or quantifying beta10 polypeptides,
CC heterodimers, and selective binding agents. The polynucleotides can be
CC used to produce cells comprising the polynucleotide, and for producing
CC polypeptides/heterodimers and identifying compounds modulating beta 10
CC polypeptide/heterodimer activity by detecting changes in activity or
CC production in the cell. They can also be used to produce implantation
CC devices to administer polypeptide/heterodimers. The present sequence
CC represents the genomic DNA encoding mouse beta-like glycoprotein hormone
CC beta10.

XX Sequence 2985 BP; 784 A; 630 C; 761 G; 810 T; 0 other;

QY Query Match 40.0%; Score 156; DB 24; Length 2985;

DB Best local similarity 85.3%; Pred. No. 8, 4e-35;

Matches 174; Conservative 0; Mismatches 30; Indels 0; Gaps 0;

QY 1 ATGAACTGGCATTCCTCTTCTTGCGCCCAATGCGCCCTCTCTTGCTGCTGCTATGCG 60

DB 1 ATGAACTGGATTAACCTTCTTCTTGCGAGTGGCCCTCTCTCTTGCTGCGCCCTGAC 60

QY 61 TGTGTCCTGGTGCCTTCAGATGCGAACCTGCGACCTTGTGGGCTGTGCGGAGGAG 120

DB 61 TCTGTCTCAGACGCTCCAGTGGAGACTGACACTTTGTGGCTGTCTGTAGAGGAA 120

QY 121 TTACTTTCTTGCGCAAGAAGCCAGGCTGCAAGGCGCTTGATCACACGATGCGCTGC 180

DB 121 TTCACTTTTCATGGCCAAAGAACCGACGCTGCAAGGAGACTTGCATCACACATGCTGC 180

QY 181 TGGGGTCCGTGAGACCTGGGAG 204

DB 181 TGGGGCCGCTGCGAGACCTGGGAG 204

RESULT 12

AA60523
ID AAN60523 standard; cDNA; 496 BP.

XX AAN60523;

XX 01-JUL-1991 (first entry)

XX Sequence encoding dog beta luteinizing hormone (LH).

XX Contraceptive; fertility control; vaccine; reproductive hormone; ss.

XX Dog.

XX Key Location/Qualifiers

XX CDS 1..54

XX mat_peptide 55..420

XX polyA_signal 457..462

XX polyA_site 496

XX W08607383-A.

XX 18-DEC-1986.

XX 04-JUN-1986; 86WO-US01226.

XX 18-JUL-1985; 85US-0756847.

XX 04-JUN-1985; 85US-0741168.

XX (BIOT-) BIOTECHN RES PARTN.

XX Talmadge KD, Fiddes JC;

XX WPI: 1986-346608/52.

XX P-PSDB; AAP60601.

DR

XX Auto-antigen vaccines conferring antigenicity using multimers
 PT etc. - useful as species specific or cross-species effective,
 PT esp. for controlling fertility in mammals

XX Example; Fig 3B; 101pp; English.

XX The patentors claim a vaccine effective against mammalian fertility
 CC comprising a vaccinia virus genome having disposed unit, in a non-
 CC essential region, a DNA sequence of formula : (Hormone)_n; n=1-20;
 CC hormone- DNA sequence derived from the sequence encoding a
 CC reproductive hormone. The hormone is esp. LH, GnRH, CG or FSH.

XX Sequence 496 BP; 66 A; 191 C; 134 G; 105 T; 0 other;

Query Match 15.8%; Score 61.6; DB 7; Length 496;
 Best Local Similarity 52.8%; Pred. No. 5.1e-08;
 Matches 133; Conservative 0; Mismatches 119; Indels 0; Gaps 0;

QY 133 GCCAAGAGCCAGGCTGCGAGGGGCGCTTGATACACACAGATGCGTGGGGTGCCTGT 192
 Db 106 GCTGGAAGAGAGCCCTGCGGCTGTGTATCATCTTACACACACCATGTGCGGCTAC 165
 QY 193 GAGACCTGGAGAAACCATTTCTGGAACCCCTATATTGAAGCCCATCATGAGCTGT 252
 Db 166 TGCCCCAGCATGTAGAGAGTGTCTGCGACGCCCTGACACCTGTGCCAGCACTGTGC 225
 QY 253 ACCTACACAGAGACCAACACAGTACTGTCAAGTGCACCACTGTGCCCGGAGTGCAC 312
 Db 226 ACCTACACAGAGCTGACATTTCTTCAATTCGCGCTCCCGGATGCCCTGTGGAGC 285
 QY 313 CCCCTTACACTATACCCGCTGCGCATCCGCTGTGACCTGCGAGCCGTGCCACTGCCAC 372
 Db 286 CCCATGTCTCTCTTCCCGCGGCTGAGCTGTGCGTGTGGGCTGCTGCTGACGCAAC 345
 QY 373 ACGAGTGTGAG 384
 Db 346 TCCGACTGTGG 357

RESULT 13

AA03844
 ID AA03844 standard; cDNA; 525 BP.

AC AA03844;

XX 24-AUG-1990 (first entry)

XX Bovine beta LH subunit.

XX Lutealizing hormone; follicle stimulating hormone;

KM recombinant cDNA; alpha subunit; beta subunit; unguulate; ss.

XX Bos taurus.

XX Key location/Qualifiers

FT CDS 3..422

FT /tag= a

FT /product=Bovine beta LH

XX MO9002757-A.

XX 22-MAR-1990.

XX 02-SEP-1988; 88WO-0030949.

XX 02-SEP-1988; 88WO-US03049.

XX (INTE-) INTEGRATED GENETICS.

XX Beck A, Bernstine E, Hsiung N, Kelton C, Lerner T, Reddy VB;
 PI Chapel SC;

DR WPI; 1990-115954/15.

XX Biologically active unguulate LH and FSH- produced by recombinant methods.

XX Disclosure; Fig 2; 66pp; English.

XX LH and FSH comprises an alpha and a beta subunit, both subunits can be
 CC synthesised in a single cell contg. an expression vector comprising
 CC heterologous DNA encoding one subunit.
 CC See also AA003843-Q03851.

XX Sequence 525 BP; 90 A; 202 C; 130 G; 103 T; 0 other;

Query Match 14.8%; Score 57.8; DB 11; Length 525;
 Best Local Similarity 51.8%; Pred. No. 6.3e-07;
 Matches 131; Conservative 0; Mismatches 122; Indels 0; Gaps 0;

QY 132 GCCAAGAGCCAGGCTGCGAGGGGCGCTTGATACACACAGATGCGTGGGGTGCCTGT 191
 Db 107 GCGTGAAGAGAGGCGCTGCGCTGTGTATCATCTTACACACAGATGTGCGCGGCTA 166
 QY 192 TGAGACCTGGGAGAAACCATTTCTGGAACCCCTATATTGAAGCCCATATGAGTCTG 251
 Db 167 CTGCCCCAGCATGAAGCGGCTGCTGCTGTATCTTCTGCGGCCCATGCCCCAGCGGCTG 226
 QY 252 TACCTACAAAGAGACCAACAGTGTACTGTCAAGCTGCCACATGNGCCCGGAGTGA 311
 Db 227 CACCTACACATGAGCTGCGCTTGCCTTGTGCGCTTCCCGGCTGCGCACTGAGTGA 286
 QY 312 CCCCTTACACTATACCCGCTGCGCATCCGCTGTGACCTGCGAGGCGTGCACCTGCCAC 371
 Db 287 CCCATGTGTCTCTTCCCGGCTGAGCTGTGACCTGTGAGCCCTGCGGCTGACGAG 346
 QY 372 CACGAGTGTGAG 384
 Db 347 CACTGACTGCGGG 359

RESULT 14

AAH41044
 ID AAH41044 standard; DNA; 535 BP.

AC AAH41044;

XX 28-AUG-2001 (first entry)

XX GTH-betaII subunit DNA.

XX Polymeric glycoprotein; goldfish; GTH; gonadotrophin; ds.

XX Carassius auratus.

XX JP2001086992-A.

XX 03-APR-2001.

XX 24-SEP-1999; 99JP-0270790.

XX 24-SEP-1999; 99JP-0270790.

XX (AJIN) AJINOMOTO KK.

XX WPI; 2001-338422/36.

XX Production of a polymeric glycoprotein by introducing a gene expressing
 PT the glycoprotein into a fish -

XX Example 1; Page 9-10; 14pp; Japanese.

XX The present invention relates to a method for the production of a
 CC polymeric glycoprotein in which a gene encoding the glycoprotein is
 CC introduced into a fish and expressed. The glycoprotein can be recovered
 CC from the embryo of the fish in which the gene was introduced or from its

CC tissue or blood. The method is used for the production of a polymeric
 CC glycoprotein. The present sequence represents the goldfish GTH
 CC (gonadotropin) beta1 subunit. DNA encoding GTH is used in an example
 CC illustrating the method of the invention.

SO Sequence 535 BP; 135 A; 141 C; 113 G; 146 T; 0 other;

Query Match 14.6%; Score 56.8; DB 22; Length 535;
 Best Local Similarity 59.1%; Pred. No. 1.2e-06;
 Matches 97; Conservative 0; Mismatches 67; Indels 0; Gaps 0;

QY 222 CCCCTATATTGAAGCCATATGAGTCTTACCTACACAGCAACAAGGTGACTGT 281
 DB 223 CCCATTTTCCACTGTCTACCAACATGTGTGACATCCGGACGCTGACGAGACTGT 282
 QY 282 CAAGCTGCCAAGCTGTGCGCGGAGTGCACCTCTACACCTATCCCTGGCCATCCG 341
 DB 283 CCGCTTGGCAGAGTCTCTCCAGGGGTGAGCCCCACATCATCCCTGTGGCTTCAG 342
 QY 342 CTGTGACTGCGGAGCGCTGTCTCCACTGCCACCGAGAGTGTGACA 385
 DB 343 CTGGAAGTGCAGCGCTGTGACATATGACACATGTGACTGTACGA 386

RESULT 15
 AA16195
 ID AA16195 standard; DNA; 5651 BP.

XX AC AA16195;

DT 29-JAN-2002 (first entry)

DE Human FSH beta encoding plasmid pBYDH1022 SEQ ID NO 6.

XX Human: FSH alpha; FSH beta; follicle stimulating hormone; glycosylation;
 KM antiinfertility; cyclic; circular; ds.

XX Chimeric - Homo sapiens.

OS Chimeric - Cytomegalovirus.

OS Synthetic.

FT Key Location/Qualifiers
 FT CDS 1231..1620
 FT /tag= a
 FT /product= "FSH beta"
 FT sig_peptide 1231..1284
 FT /tag= b
 FT mat_peptide 1285..1617
 FT /tag= c
 FT /product= "FSH beta"

PN WO200158493-A1.

PD 16-AUG-2001.

PF 09-FEB-2001; 2001WO-DK00090.

PR 11-FEB-2000; 2000DK-0000220.

PR 14-JUL-2000; 2000DK-0001092.

PA (MAXY-) MAXYGEN APS.

PI Schambye HT, Andersen KV, Van Den Hazel B, Christiansen J;
 PI Jeppesen CB;

DR WPI; 2001-607186/69.

PT New polypeptide conjugate with follicle stimulating hormone (FSH)
 PT activity, used to treat infertility, comprises polypeptide having
 PT modified FSH alpha and beta subunits with attachment group for
 PT non-polypeptide moiety -

PE Example 1; Page 77-79; 88pp; English.

XX The invention relates to new polypeptides and polypeptide conjugates
 CC exhibiting follicle stimulating hormone (FSH) activity. FSH is a dimeric
 CC hormone comprising of an alpha (AAM51709) and beta (AAM51711) subunit.
 CC The invention relates to a heterodimeric FSH conjugate comprising, a
 CC dimeric polypeptide having FSH alpha (AAM51733-AAM51800,
 CC AAM51442-AAM51449) and beta (AAM52001-AAM52104) subunits, where at least
 CC one subunit differs from corresponding wild-type subunit in that an
 CC amino acid residue containing an attachment group for a non-polypeptide
 CC molecule has been introduced or removed, especially where at least one of
 CC the FSH-alpha and FSH-beta subunits comprises at least one introduced
 CC N- or O-glycosylation site at its N-terminal and the glycosylation site
 CC being glycosylated. The polypeptides have antiinfertility activity. The
 CC polypeptides have increased functional in vivo half life and/or serum
 CC half life as compared to human FSH, replenishing insufficient endogenous
 CC FSH production in a patient. The present sequence is that of a plasmid
 CC for expression of human FSH beta.
 CC Note: The present sequence differs from that given as the full length FSH
 CC beta in SEQ ID NO 3 (AAM51711) as there is a Lys to Glu mutation at
 CC position 2 of the native signal sequence.

SO Sequence 5651 BP; 1315 A; 1493 C; 1439 G; 1404 T; 0 other;

Query Match 14.6%; Score 56.8; DB 22; Length 5651;
 Best Local Similarity 64.4%; Pred. No. 2.5e-06;
 Matches 85; Conservative 0; Mismatches 47; Indels 0; Gaps 0;

QY 249 CTGTACCTACAGGAGCAACAGAGTGAAGTGTGACGCTGCGCACTGTGCGCGGAGT 308
 DB 1434 CTGCACCTTGAAGGAGGTGTGTGACGAGCGTCCGGTCCGCGCCACCAACAGC 1493
 QY 309 CGACCCCTTCTACACCTATCCCGTGGCCATCCGCTGTGACTGCGGAGCCGTCTCACTGC 368
 DB 1494 CGACAGCCTTACACCATCCCGTGGCCACCAAGTGCACATGGGCAAGTGCAGACGCA 1553
 QY 369 CACCACGGAGTG 380
 DB 1554 CAGCACCAGACTG 1565

Search completed: October 12, 2002, 13:32:39
 Job time : 162 secs